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Abstract: The outlook for patients with rheumatoid arthritis has improved significantly over 
the last three decades with the use of disease-modifying antirheumatic drugs. However, despite 
the use of methotrexate, cytokine inhibitors, and molecules targeting T and B cells, a percent-
age of patients do not respond or lose their response over time. The autoimmune process in 
rheumatoid arthritis depends on activation of immune cells, which utilize intracellular kinases 
to respond to external stimuli such as cytokines, immune complexes, and antigens. In the past 
decade, small molecules targeting several kinases, such as p38 MAPK, Syk, and JAK have been 
developed. Several p38 MAPK inhibitors proved ineffective in treating rheumatoid arthritis. 
The Syk inhibitor, fostamatinib, proved superior to placebo in Phase II trials and is currently 
under Phase III investigation. Tofacitinib, a JAK1/3 inhibitor, was shown to be efficacious in 
two Phase III trials, while VX-509, a JAK3 inhibitor, showed promising results in a Phase II 
trial. Fostamatinib and tofacitinib were associated with increased rates of infection, elevation 
of liver enzymes, and neutropenia. Moreover, fostamatinib caused elevations of blood pressure 
and diarrhea, while tofacitinib was associated with an increase in creatinine and elevation of 
lipid levels.
Keywords: rheumatoid arthritis, kinase inhibitors, mitogen-activated phosphokinase p38, spleen 
tyrosine kinase, Janus kinases
Current treatment paradigm in rheumatoid 
arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease, characterized by infiltra-
tion of the synovium, a structure that lines the joints, with inflammatory cells. The 
thickened synovium forms a lesion called pannus that slowly destroys the cartilage 
and the bone adjacent to the joint. Both the small joints of the hands and feet and the 
larger joints such as the knees and wrists become damaged in RA, ultimately leading to 
severe functional impairment. More aggressive forms of RA also involve extra-articular 
tissues, causing lung inflammation, splenomegaly with cytopenia, skin nodules, and 
vasculitis. Therefore, treatment of RA aims at stopping the inflammatory response 
before permanent damage occurs.
The natural history of RA has changed dramatically since the 1980s with the intro-
duction of methotrexate, a potent drug with a good safety profile.1 Methotrexate, as 
compared with anti-inflammatory drugs that merely alleviate temporarily the symptoms 
of joint inflammation, changed the course of the disease, retarding or even preventing 
the development of bone erosions, thus becoming the penultimate disease-modifying 
antirheumatic drug (DMARD).
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In the 1990s, significant work on the pathophysiology 
of RA led to the development of specific DMARDs using 
monoclonal antibodies and receptor decoys. The extracellular 
cytokines, tumor necrosis factor-alpha2 and interleukin-1,3 
were the first cytokines to be successfully targeted, fol-
lowed by interleukin-6.4 Additionally, T cell activation was 
targeted using a hybrid molecule, CTLA4-Ig,5 that prevents 
the interaction between T cells and antigen-presenting cells. 
Finally, elimination of B cells using an antibody that targets 
the surface molecule CD20 was proven very effective in 
alleviating the disease.6 The efficacy and side effect profiles 
of the biologic treatments made them a mainstay of treatment 
alongside or without methotrexate.
However, these biologic treatments need to be injected 
subcutaneously or intravenously, are expensive, and have 
significant side effects, such as infection7 and immunologic 
reactions against the compound itself.8 Moreover, a signifi-
cant proportion of the patients treated with biologics and/or 
methotrexate do not respond or lose their response to the 
treatment. Therefore, oral, relatively cheap, small molecules 
targeting specific pathways could represent a valuable addi-
tion to the current DMARD armamentarium.
Efficacy measures in clinical trials
In the 1990s, the European League Against Rheumatism 
and the American College of Rheumatology (ACR) devel-
oped disease outcome measures, of which the ACR 20% 
response (ACR20)9 is widely used in most large randomized, 
placebo-controlled trials in RA. For a patient to be regarded 
as a responder based on the ACR20 response criterion, he 
or she must have at least 20% improvement in both swollen 
and tender joint counts and three out of the following five 
variables: patient and evaluator global disease activity, pain 
assessment, functional disability, and acute-phase reactants 
(sedimentation rate or C-reactive protein).
It has to be stated though that patients with 20% improve-
ment in their disease activity may still have significant dis-
ease burden and are likely not in remission. Therefore, the 
ACR50 and ACR70 responses, which represent 50% and 
70%, respectively, improvement over baseline, are routinely 
reported in RA trials and may be more important in assessing 
the effectiveness of antirheumatic treatments.
Novel targets in RA: kinase inhibitors
More recently, a new category of drugs targeting cytoplasmic 
kinases has been developed and shown to be helpful in the 
treatment of immune diseases and cancer. As stated above, 
RA is characterized by activation of several different types 
of immune cells that infiltrate the joints, ultimately leading 
to joint destruction. Successful activation of immune cells 
requires integration of external stimuli through their surface 
receptors. Once the receptor attaches to its ligand, such as a 
proinflammatory cytokine, (self)-antigen, or immune com-
plex, conformational changes lead to activation of intracellular 
kinases attached to the receptor. These enzymes phosphorylate 
downstream molecules, propagating a cascade that leads to 
transcription of genes coding effector molecules. In the case of 
RA, kinases play a central role in the aberrant immune system 
activation and hence have been targeted using small molecule 
inhibitors. Mitogen-activated phosphokinase p38 (MAPK), 
spleen tyrosine kinase (Syk), and Janus kinases (JAKs) have 
been studied extensively in clinical trials in RA (summarized 
in Table 1) and are the focus of this review.
p38 MAPK
One of the first kinases to be targeted in RA was MAPK. 
p38 MAPK is a serine-threonine kinase that is activated via 
phosphorylation by MAPK kinase.10 Activation of MAPK is 
induced by various extracellular stimuli and can result in the 
production of tumor necrosis factor-alpha and interleukin-1 
by monocytes, as well as interleukin-6.11,12 Given the impor-
tance of these cytokines in the pathophysiology of RA, it is 
not surprising that MAPK was upregulated in rheumatoid 
synovium13 and that inhibition of MAPK led to amelioration 
of the disease in experimental arthritis in rats.14
Following the promising in vitro and animal data, sev-
eral small molecules specifically targeting p38 MAPK were 
developed. However, the results from clinical trials in humans 
were largely negative. Pamapimod15,16 and VX-70217 were 
studied in conjunction with methotrexate. The effect of these 
drugs was not statistically superior to placebo. More recently, 
the results of a Phase II clinical trial of SCIO-469 did not show 
an effect either.18 Interestingly, these studies showed a biologic 
effect of MAPK inhibition, which was a decrease in the inflam-
matory index C-reactive protein in the first few weeks of treat-
ment. Unfortunately, this decrease in C-reactive protein was not 
followed by a clinical response, and the C-reactive protein levels 
gradually climbed back up. Several factors have been blamed 
for the ineffectiveness of p38 inhibitors, including inadequate 
dosing due to side effects or induction of other kinases that can 
take over the role of p38 in cell activation.
Syk
Unlike MAPK, Syk is a tyrosine kinase that associates directly 
with surface receptors, including the B cell receptor and Fcγ 
receptor, on macrophages, mast cells, and neutrophils.19 
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Myeloid-derived cells, such as osteoclasts, also express Syk, 
which makes this molecule an attractive targeting candidate 
in RA because its inhibition could theoretically target both 
inflammation and bone erosion. Indeed, the small molecule, 
R406, that blocks Syk, as well as its orally available prodrug 
R788, inhibited the development of experimental arthritis in 
rats without significantly affecting antibody production.20
In a randomized, placebo-controlled Phase II trial, R788 
(renamed fostamatinib) when added to background metho-
trexate at a stable dose was effective in meeting the primary 
outcome of ACR20 response at 12 weeks.21 Patients taking 
fostamatinib at a dose of 100 mg twice a day or 150 mg twice 
a day achieved ACR20 responses of 65% and 72%, respec-
tively, as opposed to 38% in the placebo group. ACR50 and 
ACR70 responses were also significantly better than placebo. 
The lower dose of 50 mg twice a day did not improve the 
outcome as compared with placebo. Side effects included 
diarrhea, neutropenia, alanine transferase elevation, and 
increased blood pressure. Most side effects were associated 
with the higher doses of fostamatinib. A larger study for 24 
weeks reported similar efficacy for the 100 mg and 150 mg 
twice-daily doses, although a dose effect was not seen with 
these doses.22 Side effects were similar to those seen in the 
first study, with diarrhea, neutropenia, and abdominal pain 
being significantly more common in the two treatment groups 
than in the placebo group, while upper respiratory infections 
were more common in the high-dose group as compared with 
placebo. The issue of the unexplained effect of fostamatinib 
on blood pressure was addressed thoroughly in this study. As 
in the previous smaller trial, there was an increase in mean 
blood pressure in the fostamatinib group by 5 mmHg one 
month following initiation of treatment. Some of the patients 
needed new antihypertensive agents or adjustment of the dose 
of their established antihypertensive medications.
Fostamatinib was also evaluated in patients who had 
failed treatment with biologics. This group of patients is gen-
erally the most difficult to treat, and their treatment remains 
an unmet need. Fostamatinib did not improve the ACR20 
outcome significantly over placebo,23 although some sec-
ondary outcomes showed that fostamatinib might have a 
minor effect, especially in patients with higher C-reactive 
protein at baseline. A Phase III clinical trial of fostamatinib 
is under way evaluating its efficacy in reducing inflammation 
and inhibiting erosions in patients who have a suboptimal 
response to methotrexate.
Overall, fostamatinib is a novel DMARD that is effi-
cacious in reducing inflammation and improving clinical 
activity in patients with RA. Important side effects include 
neutropenia, elevation of liver enzymes, diarrhea, infections, 
and elevation of blood pressure.
Table 1 Summary of published studies of kinase inhibitors in patients with rheumatoid arthritis
Target Compound Phase  
(duration)
Trial design ACR20 active  
compound
ACR20 
control
p38 MAPK Pamapimod II (12 weeks) Pamapimod + methotrexate  
versus methotrexate15
31%–43% 34%
II (12 weeks) Pamapimod versus methotrexate16 18%–31% 45%
VX-702 II (12 weeks) VX-702 versus placebo17 36%–40% 28%
II (12 weeks) VX-702 + methotrexate versus  
methotrexate17
40%–44% 22%
SCIO-469 II (12 weeks) SCIO-469 versus placebo18 23.1%–32.9% 24%
Syk Fostamatinib  
(R406, R788)
II (12 weeks) Fostamatinib versus placebo21 65%–72%  
(100 and 150 mg)
38%
II (24 weeks) Fostamatinib versus placebo22 57%–67% 35%
II (patients who  
failed biologics)
Fostamatinib versus placebo23 38% 37%
JAK Tofacitinib  
(CP-690,550)
IIa (6 week) Tofacitinib versus placebo25 70.5%–81.2% 29.2%
IIb (24 weeks) Tofacitinib + methotrexate  
versus methotrexate26
52.9% 33.3%
II (12 weeks) Tofacitinib versus adalimumab  
versus placebo27
39.2%–71.9% 35.9% (adalimumab) 
22% (placebo)
III (6 months,  
endpoint at 3 months)
Tofacitinib versus placebo 59.8% (5 mg group),  
65.7% (10 mg group)
26.7%
III (12 months,  
endpoint at 6 months)
Tofacitinib + methotrexate  
versus adalimumab + methotrexate  
versus methotrexate
51.5% (5 mg group),  
52.6% (10 mg group)
47.2% (adalimumab) 
28.3% (placebo)
Abbreviation: ACR, American College of Rheumatology.
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JAK inhibitors
The JAK family of tyrosine kinases was first recognized 
20 years ago as essential in interferon-dependent signaling. 
Later, these kinases were found to be associated with a 
variety of cytokine receptors, such as those for interleukin-2, 
interleukin-12, and interleukin-6, as well as the receptor for 
erythropoietin. Upon ligation of these receptors with their 
ligand cytokine, JAKs become activated, phosphorylate their 
receptors, and recruit the signal transducers and activators of 
transcription proteins, leading to activation of the relevant 
genes. Because cytokine receptors are expressed on most 
immune cells, including T cells, B cells, monocytes, and 
granulocytes, JAK-mediated signaling is pivotal in immune 
activation. To date, four members of this family are known, 
ie, JAK1, JAK2, JAK3, and TYK2.
The best studied JAK inhibitor in RA is tofacitinib (also 
known as CP-690,550), a molecule that primarily inhibits 
JAK1 and JAK3 and, to a lesser extent, JAK2. This is thought 
to be advantageous in terms of potential hematologic toxicity, 
because hematopoietic cytokine receptors, such as the 
erythropoietin receptor, associate with JAK2 homodimers. 
Tofacitinib was shown to be effective in preventing cartilage 
damage in mouse and rat models of experimental arthritis.24 
After small proof-of-concept trials in humans, Kremer et al 
conducted a six-week Phase IIa study25 that evaluated patients 
who either could not tolerate or did not respond to metho-
trexate and/or one tumor necrosis factor-alpha inhibitor. 
The patients were randomized to CP-690,550 5 mg twice a 
day, 15 mg twice a day, 30 mg twice a day, or placebo. The 
investigators described a rapid (within 1–2 weeks) response 
to the drug, with ACR20 responses of 70.5%, 81.2%, and 
76.4% in the 5 mg, 15 mg, and 30 mg dose groups, as opposed 
to 29.2% in the placebo group.
In a Phase IIb study, tofacitinib at various doses (20 mg 
once a day or 1 mg, 3 mg, 5 mg, 10 mg, and 15 mg twice 
daily) or placebo was added onto stable background 
  methotrexate.26 The patients enrolled in the study had active 
disease despite methotrexate at a mean dose of 16–17 mg per 
week. Treatment with 3 mg twice daily or more of tofacitinib 
resulted in higher response rates than for placebo starting 
as early as week 2 and sustained through to week 24 of 
treatment. In particular, the ACR20 response rate was 52.9% 
for the 3 mg twice-daily group compared with 33.3% for 
the placebo group. Adverse events that seemed to be associ-
ated with tofacitinib included: infections (five serious, with 
one death); a decrease in neutrophil count, with one patient 
developing moderate neutropenia but no patient develop-
ing severe neutropenia; and small increases in creatinine 
levels, transaminases, and lipid levels. Interestingly, patients 
  receiving lower doses of tofacitinib had mild improve-
ment in their hemoglobin possibly associated with better 
disease control, while patients on higher doses had a mild 
decrease in their hemoglobin levels, possibly reflecting 
JAK2 inhibition.
In a related study, Fleischmann et al27 compared 
tofacitinib with adalimumab, a tumor necrosis factor-alpha 
inhibitor, in patients with active RA. Impressively, tofaci-
tinib monotherapy resulted in a dose-dependent response 
that was better than both adalimumab or placebo. At week 
12, the ACR20 responses were between 39.2% for the 3 mg 
twice-daily dose and 71.9% for the 15 mg twice-daily 
dose. This compared with 22% for placebo and 35.9% for 
adalimumab. Similarly, half the patients on the high dose 
of tofacitinib reached the ACR50 response mark and a 
quarter of them reached ACR70. The rate and severity of 
adverse events was comparable with that in the study by 
Kremer et al.25
Following on from these trials, several pivotal Phase III 
trials of tofacitinib in RA were recently published. Patients 
who failed at least one biologic or conventional DMARD 
were randomized to receive placebo or tofacitinib 5 mg 
twice a day (low dose) or 10 mg twice a day (high dose) 
for 6 months. Patients on the placebo arm were switched to 
active medication at three months. The primary endpoint 
of ACR20 was met in the study, with the two tofacitinib 
groups reaching ACR20 responses of 59.8% (low dose) and 
65.7% (high dose) versus 26.7% for the placebo group.28 
The side effect profile of tofacitinib appeared similar to 
that in the Phase II trials, ie, infections, lipid level eleva-
tion, and hematologic effects (neutropenia). Neutropenia 
(mild in general) developed in 3.1% and 3.7% of patients 
in the two tofacitinib groups (5 mg and 10 mg, respectively) 
versus ,1% in the placebo group. Seven serious infections 
were observed during the trial, four in the high-dose group 
(bronchitis, tuberculous pleural effusion, pyelonephritis, and 
liver abscess) and three cases of cellulitis in two patients, 
one in the low-dose group and one in the placebo group. 
Increased creatinine was observed, but this was mild, with 
only three patients having an increase of more than 50% 
from baseline and still within normal limits.
In a parallel 12-month study, patients on methotrexate 
were assigned to the same two doses of tofacitinib as above, 
adalimumab 40 mg every other week, or placebo. The 
patients on placebo who did not achieve an improvement of 
at least 20% by three months were switched to tofacitinib. 
At month 6, tofacitinib was found to be equivalent to 
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adalimumab,29 with ACR20 responses of 51.5%, 52.6%, and 
47.2% for low-dose tofacitinib, high-dose tofacitinib, and 
adalimumab, respectively. This was in contrast with a 28.3% 
ACR20 response rate in the placebo group. The side effects 
observed were similar to the monotherapy study, albeit with 
increased rates of infection and two cases of pulmonary 
tuberculosis in the high-dose group. A very mild decrease 
in hemoglobin was observed in patients receiving tofacitinib 
10 mg twice daily with methotrexate.
Data from the clinical trials and long-term extension trials 
representing 5651 patient-years showed that the incidence of 
malignancy (excluding nonmelanoma skin cancer) was 0.89 
per 1000 patient-years.30 These malignancies mainly included 
lung cancer, breast cancer, and lymphomas, and their overall 
incidence did not significantly differ from the observed rate in 
patients with severe RA taking DMARDs. Similarly, cardio-
vascular events over 2098.2 patient-years seemed to be similar 
to those seen in patients with RA.31 However, the follow-up 
period was probably inadequate to exclude small increases in 
malignancies and cardiovascular events convincingly.
Interim analysis of a related study at 12 months showed 
that tofacitinib 5 mg and 10 mg twice daily was superior to 
placebo in reducing the progression of structural damage, 
ie, bony erosions.32
Several other JAK inhibitors are currently in various 
stages of development. VX-509, a selective JAK3 inhibitor, 
was evaluated in a Phase II dose-finding trial as monotherapy 
for patients with active RA who had failed nonbiologic 
DMARDs.33 VX-509 showed a dose-dependent increase in 
ACR20 versus placebo (ACR20 66%, 65%, 61%, 39% and 
29% in 150 mg, 100 mg, 50 mg, 25 mg twice a day, or placebo 
groups, respectively). Again, mild elevations of low-density 
and high-density lipoprotein levels were observed, but with 
no effects on hemoglobin, neutrophils, or creatinine. Given 
the short period of the trial (12 weeks) and the low number 
of patients (40–41 per group), no firm conclusion regarding 
side effects can be determined. GLPG0634, a JAK1 inhibitor 
and INCB028050, a JAK1/2 inhibitor, are also being evalu-
ated for their effectiveness in RA.
JAK inhibitors are efficacious oral medications in RA and 
can be used as monotherapy or with background methotrex-
ate treatment. Dose-related side effects include infections, 
increased lipid levels, anemia, neutropenia, elevation of 
transaminases, and possibly changes in renal function.
Conclusion
The use of biologics over the last 10 years has improved the 
outcomes for RA patients, building on the previous success 
of methotrexate as a potent DMARD. Challenges remain, 
because a significant percentage of patients either cannot 
tolerate or obtain incomplete relief from these medications. 
Additionally, the cost of therapy remains very high, and the 
patients have to undergo either intravenous or subcutaneous 
injections.
The small molecules that target kinases are very potent 
in alleviating symptoms and seem to prevent structural dam-
age, according to preliminary data. In particular, Syk and 
JAK inhibitors are in line to be approved as therapies for 
RA. These medications may represent a major shift in the 
treatment of RA. Given their cost and ease of administration, 
one could argue that they should be the first drugs to add in 
patients with RA who are intolerant or do not respond to 
methotrexate. Their precise role will need to be defined in 
real-world clinical practice.
As these drugs move towards approval, their long-term 
safety will need to be addressed as well. Aside from their 
expected side effects, such as suppression of the immune 
system, kinase inhibitors show class-specific adverse events 
that possibly represent off-target effects. Fostamatinib was 
associated with increased blood pressure whereas JAK 
inhibitors caused elevation of lipid levels. These side effects 
may increase the risk of cardiovascular disease, a known 
complication of RA. Therefore, the effects of fostamatinib 
and tofacitinib on cardiovascular risk factors will need to 
be investigated thoroughly during the pivotal Phase III 
trials, in Phase IV extension trials, and post-marketing 
surveillance.
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